BioDlink International Co Ltd
01875
Company Profile
Business description
BioDlink International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families, as well as medical professionals. The company has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The company generates maximum revenues from Mainland China.
Contact
120 Changyang Street
Suzhou Industrial Park
Suzhou215024
CHNT: +86 51262965186
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
604
Stocks News & Analysis
stocks
Coca-Cola earnings: Innovation and brand strength underpin growth
We plan to raise our fair value estimate of Coca-Cola stock.
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,309.30 | 22.60 | -0.24% |
| CAC 40 | 8,258.86 | 52.79 | 0.64% |
| DAX 40 | 24,330.03 | 71.23 | 0.29% |
| Dow JONES (US) | 46,924.74 | 218.16 | 0.47% |
| FTSE 100 | 9,426.99 | 23.42 | 0.25% |
| HKSE | 26,027.55 | 168.72 | 0.65% |
| NASDAQ | 22,953.67 | 36.88 | -0.16% |
| Nikkei 225 | 48,711.17 | 604.89 | -1.23% |
| NZX 50 Index | 13,332.44 | 45.41 | -0.34% |
| S&P 500 | 6,735.35 | 0.22 | 0.00% |
| S&P/ASX 200 | 9,023.30 | 17.00 | -0.19% |
| SSE Composite Index | 3,916.33 | 52.44 | 1.36% |